Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN) (WARFARIN)
Anti-coagulation Therapy, DVT, Pulmonary Embolism
About this trial
This is an interventional prevention trial for Anti-coagulation Therapy focused on measuring warfarin, genetic testing, personalized medicine, anti-coagulants, coumadin
Eligibility Criteria
Inclusion Criteria:
- Men and women at least 65 years old
- Beginning warfarin (0 - 3 doses of warfarin taken at the time of enrollment) for a variety of diseases or conditions that require at least 30 days oral anticoagulation with target INR ≥ 2.0
Exclusion Criteria:
- Unable to complete the study materials (questionnaires) with or without assistance (for example, those with dementia)
- A previous genetically determined warfarin dose
- The treating physician does not agree to use the recommended warfarin dose or feels that the patient should not be enrolled in the study
Sites / Locations
- Veterans' Affairs Medical Center
- Cardiovascular Consultants - Thunderbird
- Cardiovascular Consultants - Phoenix
- Orthoarkansas
- Comprehensive Cardiovascular Specialists
- St. Joseph's Medical Center
- Colorado Heart & Vascular
- Okaloosa Heart & Vascular
- Infinity-Northshore
- Infinity Clinical Research
- Heart Rhythm Specialists
- Sarasota Memorial Hospital
- Grady Hospital
- Cardiology of Atlanta
- Atlanta Heart Group
- Southern Heart Research Institute
- St. Alphonsus Regional Medical Center
- Rush University Medical Center
- Rockford Cardiovascular Research Foundation
- Carle Foundation
- Community Hospital Anderson
- St. Mary's
- Medical Consultants, PC
- NECCR
- Henry Ford Hospital
- Thoracic and Cardiovascular Institute
- Kansas City Heart Foundation
- Cox Medical Center
- Billings Clinic
- Nebraska Heart Institute
- Nebraska Heart
- Alegent
- Hackensack Medical Center
- New Mexico Heart Institute
- Mission Hospital
- Sanford Health Research
- Aultman Hospital
- The Christ Hospital
- Bend Memorial Clinic
- Corvallis Clinic
- Central Bucks Cardiology
- Palmetto Health Richland
- Carolina Cardiology
- St. Thomas Research Institute
- Texas Cardiac Arrhythmia
- Nexxus Research
- Legacy Heart Center
- Scott & White
- Providence Health Network
- Intermountain Medical Center
- Overlake Hospital
- Family Health Care of Ellensburg
- Polyclinic
- Swedish Hospital
- Franciscan Research Center
- Marshfield Clinic Research Foundation
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
No Intervention
Experimental
Randomized - Genetic
Randomized - Clinical
Registry
Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website